What Is KPV?
A tripeptide fragment of α-MSH — the body's primary anti-inflammatory hormone — that directly restores what chronic inflammation destroys.
KPV (Lysine-Proline-Valine) is a synthetic tripeptide derived from the C-terminal sequence of α-MSH (alpha-Melanocyte Stimulating Hormone) — the body's primary endogenous anti-inflammatory hormone. It represents the minimal active fragment of α-MSH responsible for its anti-inflammatory and immune-modulating properties.
α-MSH is produced by the pituitary gland and acts as a master regulator of the body's inflammatory response. In healthy individuals, α-MSH keeps inflammation appropriately controlled — resolving acute inflammation after injury or infection and preventing the chronic low-level inflammation that drives so many age-related diseases. In people with Chronic Inflammatory Response Syndrome (CIRS), mold illness, or certain chronic infections, α-MSH levels become critically depleted — leaving the inflammatory cascade with no brake.
KPV directly restores the α-MSH signaling pathway — providing the anti-inflammatory signal that depleted α-MSH can no longer deliver. This makes it not just an anti-inflammatory compound, but a targeted restoration of a specific failed biological control system.
In CIRS patients, a vicious cycle develops: depleted α-MSH allows MARCONS bacteria (Multiple Antibiotic Resistant Coagulase Negative Staph) to colonize the nasal passages. MARCONS actively produces enzymes that destroy α-MSH — further depleting the hormone that would otherwise clear them. KPV breaks this cycle by directly restoring the α-MSH pathway, creating an environment where MARCONS can be cleared and the inflammatory cascade can finally resolve.
How Does KPV Work?
Four mechanisms explain KPV's anti-inflammatory and immune-modulating effects.
KPV directly activates melanocortin receptors (MC1R, MC3R, MC4R) — the same receptors that α-MSH signals through. By providing this receptor activation, KPV restores the anti-inflammatory signaling cascade that depleted α-MSH can no longer deliver. This is the central mechanism that makes KPV uniquely relevant to CIRS and chronic inflammatory conditions.
KPV directly inhibits NF-κB — the master transcription factor that controls the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. NF-κB overactivation is a hallmark of chronic inflammatory conditions; KPV's ability to suppress it at the transcriptional level produces broad downstream anti-inflammatory effects.
KPV has shown direct protective effects on intestinal epithelial cells — reducing gut permeability, suppressing intestinal inflammation, and supporting the integrity of the gut lining. This mechanism makes KPV particularly relevant for the gut component of CIRS and for inflammatory bowel conditions where the intestinal barrier is compromised.
KPV modulates macrophage and dendritic cell activity — reducing the production of pro-inflammatory mediators while supporting appropriate immune function. This immune modulation is regulatory rather than suppressive — it normalizes dysregulated immune responses rather than broadly suppressing immunity.
Understanding Why KPV is Essential for CIRS
The MARCONS-α-MSH destruction cycle — and how KPV breaks it.
What Is KPV Used For?
Targeted applications for chronic inflammatory conditions — with CIRS as the primary indication.
- CIRS & Mold IllnessThe primary application. KPV is the α-MSH restoration anchor of the Shoemaker CIRS protocol — used alongside Thymosin Alpha-1 for comprehensive immune rebalancing. The 4-month minimum duration reflects the time required to fully restore α-MSH pathway function and break the MARCONS-α-MSH destruction cycle.
- Inflammatory Bowel DiseaseKPV's direct gut epithelial protection and NF-κB inhibition make it a meaningful intervention for Crohn's disease and ulcerative colitis — conditions characterized by exactly the kind of NF-κB-driven intestinal inflammation that KPV targets. Oral delivery is particularly relevant for IBD given its direct contact with the gut lining.
- Leaky Gut & Gut PermeabilityBeyond IBD, KPV supports gut barrier integrity broadly — relevant for the subclinical gut permeability that contributes to systemic inflammation, food sensitivities, and immune dysregulation in many chronic health conditions.
- Long COVID & Post-Viral SyndromePost-viral syndromes — including Long COVID — increasingly fit the CIRS framework, with many patients showing depleted α-MSH and the same biotoxin-driven inflammatory pattern. KPV is being applied by CIRS-trained practitioners to Long COVID with meaningful clinical results.
- Chronic Lyme & Co-infectionsBorrelia and associated co-infections drive the same HLA-DR-mediated biotoxin retention and α-MSH depletion pattern as mold illness. KPV addresses the inflammatory cascade component of chronic Lyme regardless of whether active infection is still present.
- General Chronic Inflammation & InflammagingFor adults with elevated inflammatory markers (hsCRP, TGF-β1) without a clear CIRS diagnosis, KPV's NF-κB inhibition and immune modulation provide meaningful anti-inflammaging support as part of a broader longevity protocol.
How to Use KPV
Duration is the most critical protocol variable — 4 months minimum is non-negotiable for CIRS applications.
Do not cycle off KPV early in CIRS protocols. The most common practitioner error in CIRS treatment is discontinuing KPV before the α-MSH pathway is fully restored — which allows MARCONS to re-establish and the destruction cycle to resume from scratch. The 4-month minimum is not arbitrary — it reflects the biological time required to restore α-MSH signaling to a level that can self-sustain. Work with a CIRS-trained practitioner to determine your specific duration based on serial α-MSH lab testing.
KPV in a Chronic Inflammation Stack
KPV anchors the immune regulation layer — combined with compounds that address the tissue damage inflammation leaves behind.
- +KPV + Thymosin Alpha-1 — The definitive CIRS combination. Thymosin Alpha-1 restores appropriate immune regulation — normalizing the dysregulated TGF-β1 driven inflammatory cascade. KPV restores the α-MSH pathway and breaks the MARCONS cycle. Together they address CIRS from two distinct but complementary immune angles — Thymosin Alpha-1 at the TGF-β1 / T-cell regulation level, KPV at the α-MSH / melanocortin receptor level. This is the anchor combination of the Shoemaker Protocol peptide approach.
- +KPV + BPC-157 — CIRS reliably damages gut integrity — and gut permeability is both a consequence and driver of ongoing systemic inflammation. BPC-157 repairs the gut lining, reduces intestinal inflammation, and addresses the leaky gut component of CIRS that keeps the inflammatory cycle running. KPV provides the immune modulation; BPC-157 repairs the structural gut damage. A complementary and synergistic combination for any chronic inflammatory condition with a gut component.
- +KPV + Epithalon — CIRS patients almost universally experience disrupted restorative sleep — which amplifies the inflammatory cascade. Epithalon restores deep sleep and REM through pineal gland support, which also supports the same α-MSH-related pathway disrupted by CIRS. Additionally addresses the accelerated telomere shortening driven by chronic systemic inflammation — a meaningful longevity consideration for long-term CIRS sufferers.
- +KPV + NAD+ — Chronic inflammation is one of the primary drivers of NAD+ depletion through PARP overactivation. As CIRS-driven inflammation is reduced by KPV, NAD+ restoration becomes more efficient — less is consumed by damage repair and more is available for energy production and sirtuin activity. A meaningful metabolic combination for CIRS recovery.
Frequently Asked Questions
The 4-month minimum reflects the biological time required to restore α-MSH pathway function to a level that can self-sustain after MARCONS clearance. α-MSH restoration is not a switch that flips — it's a gradual reestablishment of receptor sensitivity and signaling cascade function. Stopping early leaves the pathway partially restored, allowing MARCONS to re-establish and the destruction cycle to resume. This is the single most common protocol error in CIRS treatment — and the most consequential.
Both are used clinically — the choice depends on the primary application. For gut-specific inflammation (IBD, leaky gut), oral delivery provides direct contact with intestinal tissue and is generally preferred. For systemic CIRS protocols, subcutaneous injection provides more reliable systemic bioavailability. Some practitioners use both simultaneously — oral for gut coverage, SubQ for systemic effect. Discuss delivery preferences with your CIRS-trained provider.
For CIRS protocols — yes, ideally. Baseline α-MSH testing confirms the deficiency that KPV is addressing and gives you a marker to track restoration against. Retesting at 4 months guides the decision about whether to continue, adjust dose, or transition to maintenance. For general gut inflammation or anti-inflammaging use without a CIRS diagnosis, baseline testing is less critical but still provides useful information.
Yes — KPV's anti-inflammatory mechanisms are relevant beyond formal CIRS. Its NF-κB inhibition and gut epithelial protection make it meaningful for IBD, leaky gut, Long COVID, post-viral syndromes, and general inflammaging protocols. The CIRS-specific 4-month minimum applies primarily to the α-MSH restoration goal — for other applications, protocol duration is guided by the specific condition and clinical response.
For CIRS: α-MSH (primary marker), TGF-β1, C4a, MMP-9. For general inflammation: hsCRP (high sensitivity), ESR. For gut protocols: calprotectin (intestinal inflammation marker), zonulin (gut permeability). Retest at 8–12 weeks to assess response — or at 4 months for CIRS-specific α-MSH restoration tracking.
One-time purchase — instant PDF download
This page is for educational purposes only and does not constitute medical advice. KPV is not FDA-approved for any indication. CIRS requires diagnosis and management by a qualified, trained physician. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol — particularly for CIRS where improper protocol sequencing can worsen outcomes. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.